Table 3.
Virucidal effects of CAC-717 on various RNA viruses. Viral titer is shown as log10 TCID50/25 μL (mean ± SE). Values are representative values from two separate experiments.
| Viruses | Solution | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CAC-717 | CAC-717 + HEPES 1 | Tap Water | Maintenance Medium | ||||||
| 2 s | 10 s | 30 s | 1 min | 15 min | 30 min and 60 min | 60 min | 60 min | 60 min | |
| Enveloped | |||||||||
| Paramyxoviridae | |||||||||
| BPIV-3 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 6.21 ± 0.38 | 6.33 ± 0.25 | 6.58 ± 0.00 |
| BRSV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.58 ± 0.00 | 3.58 ± 0.00 | 3.83 ± 0.00 |
| CDV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.58 ± 0.25 | 3.46 ± 0.13 | 3.58 ± 0.00 |
| NDV | 4.21 ± 0.13 | 4.08 ± 0.00 | 3.71 ± 0.13 | 3.46 ± 0.13 | 2.08 ± 0.00 ** | ≤0.58 * | 5.71 ± 0.13 | 5.33 ± 0.25 | 5.46 ± 0.13 |
| Rhabdoviridae | |||||||||
| VSV | 6.08 ± 0.00 | 6.25 ± 0.25 | 6.08 ± 0.00 | 5.46 ± 0.13 | 2.08 ± 0.25 * | ≤0.58 * | 6.33 ± 0.00 | 5.33 ± 0.00 | 6.08 ± 0.25 |
| Coronaviridae | |||||||||
| SARS-CoV-2 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.46 ± 0.13 | 4.46 ± 0.13 | 4.58 ± 0.00 |
| BCoV | ≤0.58 * | ≤0.5 *8 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 5.08 ± 0.00 | 5.33 ± 0.25 | 5.33 ± 0.00 |
| Orthomyxoviridae | |||||||||
| SwIV (H1N1) | 2.83 ± 0.25 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.25 | 5.08 ± 0.25 | 5.21 ± 0.13 |
| EqIV (H3N8) | 3.08 ± 0.00 | 1.46 ± 0.13 | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.33 ± 0.00 | 3.21 ± 0.13 | 3.83 ± 0.00 |
| Flaviviridae | |||||||||
| BVDV-I | 4.58 ± 0.00 | 4.08 ± 0.00 | 3.83 ± 0.00 | 3.83 ± 0.25 | 1.96 ± 0.13 | ≤0.58 * | 4.21 ± 0.13 | 4.33 ± 0.00 | 4.71 ± 0.13 |
| BVDV-II | 4.58 ± 0.00 | 4.33 ± 0.00 | 4.46 ± 0.13 | 4.71 ± 0.13 | 2.46 ± 0.13 | ≤0.58 * | 4.96 ± 0.13 | 4.71 ± 0.13 | 4.71 ± 0.13 |
| Non-enveloped | |||||||||
| Picornaviridae | |||||||||
| FMDV type A | ≤0.5 *,2 | 5.00 ± 0.13 | 5.38 ± 0.13 | ||||||
| type O | ≤0.5 **,2 | 4.25± 0.00 | 4.00 ± 0.00 | ||||||
| type Asia 1 | ≤0.5 *,2 | 4.00± 0.00 | 4.63 ± 0.13 | ||||||
| BRBV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.21 ± 0.13 | 4.21 ± 0.13 | 4.71 ± 0.13 |
| Caliciviridae | |||||||||
| FCV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 7.08 ± 0.25 | 6.33 ± 0.00 | 6.58 ± 0.00 |
| Reoviridae | |||||||||
| BRoV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.00 | 4.58 ± 0.00 | 4.96 ± 0.13 |
| BuORV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.83 ± 0.00 | 3.71 ± 0.13 | 3.96 ± 0.13 |
1 Nine volumes of CAC-717 were pretreated with one volume of 1.0 M HEPES buffer (pH 7.2). 2 Viral titers after incubation for 60 min; * A reduction in viral titer of ≥4 log10 relative to treatment with maintenance medium; ** A reduction in viral titer of ≥3 log10 relative to treatment with maintenance medium.